Femasys (FEMY) Q1 2025 earnings summary

Executive summary

• Achieved 25.9% year-over-year sales growth to $341,264 in Q1 2025, driven by increased FemaSeed sales.

• Announced CE mark certification for FemBloc delivery system in Europe, with full system approval pending and strategic partnerships in Europe.

• Expanded international regulatory approvals for FemaSeed and diagnostic devices in the UK and Israel.

• Ongoing pivotal clinical trial for FemBloc in the U.S.; regulatory progress in multiple regions.

• Net loss widened to $5,896,839 from $3,599,510 year-over-year, reflecting higher R&D and commercial investments.

Financial highlights

• Revenue rose 25.9% to $341,264 compared to Q1 2024.

• Operating expenses increased 55.9% to $5.7 million, mainly due to R&D and sales team expansion.

• Net loss per share was $(0.23), compared to $(0.17) in Q1 2024.

• Cash and cash equivalents at quarter-end were $3.8 million.

• Accumulated deficit reached $133.1 million as of March 31, 2025.

Outlook and guidance

• Current cash and anticipated revenues expected to fund operations into early Q3 2025; additional financing required for a 12-month runway.

• Substantial doubt exists about ability to continue as a going concern without new capital.

• Anticipates full regulatory approval for FemBloc in Europe by mid-2025, with commercialization to follow.

• Continued investment planned in FemBloc pivotal trial, R&D, and commercialization efforts.